H2R Friday, 03/01/19 10:17:01 AM Re: H2R post# 170 Post # of 196 And PTLA beats on revenue! https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-revenue and http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2389690 Quote:Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update – Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May – – Signed $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management – [...] Total revenues for the fourth quarter of 2018 were $15.3 million, compared with $9.8 million for the fourth quarter of 2017. This includes $14.0 million in net product revenues from Andexxa sales, $35 thousand in revenues from Bevyxxa® sales and $1.2 million in collaboration and license revenues. Total revenues for the full year 2018 were $40.1 million, compared with $22.5 million for the full year 2017. Please see the tables at the end of this press release for a detailed breakdown of revenues. They are moving!